News
A phase I/II study of carfilzomib, iberdomide (CC-220), and dexamethasone (KID) in patients with newly diagnosed transplant-eligible multiple myeloma.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback